Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | "ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist with an IC50 of 0.26 nM, utilized for pulmonary arterial hypertension (PAH) research. This compound demonstrates efficacy in mitigating monocrotaline-induced PAH in a rat model [1]." |
In vivo | Administered orally at 150 mg/kg/day and 300 mg/kg/day starting 48 hours post-MCT treatment for 21 to 26 days, ET receptor antagonist 3 (compound 17d) significantly reduced mean pulmonary arterial pressure (mPAP) in MCT-exposed rats, decreased levels of HIF1α, ANP, and TNNI3, exhibited antioxidant activity, and inhibited lipid peroxidation [1]. |
Molecular Weight | 548.61 |
Formula | C27H28N6O5S |
Cas No. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.